CELL AND GENE THERAPY INSIGHTS

February 2026 Issue

Volume 12 Issue 1

Cell and Gene Therapy Insights Volume 12 Issue 1
Download PDF

Featuring

Issue Spotlight: Cellular immunotherapies: targeting new frontiers
Other articles
Webinars

SPOTLIGHT

Cellular immunotherapies: targeting new frontiers
Yu Cao
Guest Editor:
Yu Cao, Vice President and Global Head at Geneditbio

Editorial

The next era of cell therapy

The next era of cell therapy

Yu Cao
25 February
Read

Expert Insight

Solid tumors and advanced therapies: why science alone will not deliver the cure

Solid tumors and advanced therapies: why science alone will not deliver the cure

Arnaud Deladeriere
25 February
Read
The cryo-sensitivity of NK cells: overcoming post-thaw decline

The cryo-sensitivity of NK cells: overcoming post-thaw decline

Jason Acker
23 February
Read

Commentary

Systemization is key to fulfilling T cell therapy’s promise in cancer

Systemization is key to fulfilling T cell therapy’s promise in cancer

Reagan Jarvis
19 February
Read
Role of supportive care in the future of cell therapies

Role of supportive care in the future of cell therapies

Liam Tremble, Paula Maguire
4 February
Read
In vivo CAR therapy: quo vadis?

In vivo CAR therapy: quo vadis?

Adrian Bot, Xianghong Li
4 February
Read

Viewpoint

CMC considerations on in vivo CAR-T

CMC considerations on in vivo CAR-T

Dehui Kong
11 December 2025
Read

Interview

The next fro​​​​ntier of in vivo CAR-T: a conversation with Shon Green

The next fro​​​​ntier of in vivo CAR-T: a conversation with Shon Green

Shon Green
9 January
Read
Leaping forward: how China’s biotech evolution is capturing the in vivo CAR-T frontier

Leaping forward: how China’s biotech evolution is capturing the in vivo CAR-T frontier

Zhenghong Gao
5 January
Read

articles

Expert Insight

Integration site analysis in engineered T cell therapies: what we measure, what we miss, and what regulators expect

Integration site analysis in engineered T cell therapies: what we measure, what we miss, and what regulators expect

Deividas Pazeraitis, Juozas Kupčinskas
23 February
Read
Translating both a cure and a commercialization pathway: insights into a breakthrough gene therapy company’s journey

Translating both a cure and a commercialization pathway: insights into a breakthrough gene therapy company’s journey

Daniel Drozdov, Nektarios Oraiopoulos
21 January
Read

Review

An analysis of advanced therapy medicinal products regulatory landscape in ICH member countries: opportunities and challenges

An analysis of advanced therapy medicinal products regulatory landscape in ICH member countries: opportunities and challenges

S Kellathur, J HO Garbe, S Beattie et al.
23 February
Read

Innovator Insight

Engineering extracellular vesicles (exosomes) for nucleic acid delivery: exoASO‑STAT6® exosomes as a case study

Engineering extracellular vesicles (exosomes) for nucleic acid delivery: exoASO‑STAT6® exosomes as a case study

Vijetha Bhat
12 March
Read
Streamlined dPCR workflow for lentiviral characterization and QC of cell and gene therapies

Streamlined dPCR workflow for lentiviral characterization and QC of cell and gene therapies

Ruth Klaver, Miroslav Vranes, David Dobnik
9 February
Read
Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Scaling AAV5 production from bench to industrial scale: strategies for efficient, de-risked manufacturing

Sara Krekels, Anne MacIntyre
19 January
Read
Accelerating AAV process development with high-throughput strategies

Accelerating AAV process development with high-throughput strategies

K Vera, P Kusumanchi, D Matuszek et al.
19 January
Read

FastFacts

Advancing cell dissociation in bioprocessing: a novel, high purity trypsin-like enzyme for GMP workflows

Advancing cell dissociation in bioprocessing: a novel, high purity trypsin-like enzyme for GMP workflows

Tjebbe Van Der Meer
29 January
Read

Interview

Advocacy at warp speed: delivering the first gene replacement therapy for SLC6A1

Advocacy at warp speed: delivering the first gene replacement therapy for SLC6A1

Amber Freed
4 February
Read

Industry Insights

Industry Insights: Long-term follow-up data and clinical holds define the start of 2026

Industry Insights: Long-term follow-up data and clinical holds define the start of 2026

Abigail Pinchbeck
12 March
Read
Industry Insights: From rare disease to chronic indications, cell and gene therapies broaden their impact

Industry Insights: From rare disease to chronic indications, cell and gene therapies broaden their impact

Abigail Pinchbeck
22 January
Read

Tech Showcase

Scaling lentiviral vector manufacturing without tradeoffs: achieving higher purity and lower COGS through smarter bioprocessing

Scaling lentiviral vector manufacturing without tradeoffs: achieving higher purity and lower COGS through smarter bioprocessing

Thomas Robert
5 March
Read

Webinars